Aspirin 81mg

Phase 3

HeartSciences Inc. (HSCSW)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

HSCSWPhase 3

Aspirin 81mg Phase 3 Est. Readout

Aspirin 81mg• Pulmonary Disease, Chronic Obstructive48

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

2 competitors in Pulmonary Disease, Chronic Obstructive

Drug Information

Target Indication

Pulmonary Disease, Chronic Obstructive

Clinical Trial

NCT05265299

Last updated: 8/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

HSCSW

HeartSciences Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

triamcinolonePhase 3

Lung Diseases

Fresh frozen plasma transfusionPhase 3

Blood Coagulation Disorders

Sinerem administrationPhase 3

Aortic Aneurysm

Bupropion HCl ERPhase 3

Acute Coronary Syndrome

0.625 mg of conjugated equine estrogenPhase 3

Heart Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts